lobbying_activities: 2301292

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2301292	a0878609-ac72-4524-8e58-ad4f6ca46dde	Q2	RED+BLUE STRATEGIES	400693064	COHERUS BIOSCIENCES	2019	second_quarter	PHA	S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.	Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),SENATE	60000		0	0	2019-07-11T10:06:10.783000-04:00